The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
An achieved biomedical engineer who research the biophysical setting of mind most cancers has been named director of the Fralin Biomedical Analysis Institute at VTC’s...
Roanoke philanthropists Nick and Jenny Taubman have given Carilion Clinic $25 million to open a state-of-the-art most cancers analysis heart on the Virginia...
